Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback